Waverley Pharma Inc(WAVE-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.025
Day High0.025
Open:0.025
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Newsfile
Upcoming Meeting Dates - April 20, 2026
AI-generated - The Globe and Mail
Waverley Pharma: Top 10 Undervalued Biotechnology Industry Stocks (WAVE)
AI-generated - The Globe and Mail
Waverley Pharma: Top 10 Undervalued Biotechnology Industry Stocks (WAVE)
AI-generated - The Globe and Mail
Waverley Pharma: Top 10 Undervalued Biotechnology Industry Stocks (WAVE)
AI-generated - The Globe and Mail
Waverley Pharma: Top 10 Undervalued Biotechnology Industry Stocks (WAVE)
AI-generated - The Globe and Mail
Waverley Pharma: Top 10 Undervalued Biotechnology Industry Stocks (WAVE)
AI-generated - The Globe and Mail
Waverley Pharma: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (WAVE)
Newswire.ca
Waverley Pharma Acquires US based Pharmacy
Newswire.ca
Waverley Pharma Announces Annual and Special Meeting Election Results
Newswire.ca
Waverley Pharma Business Update
Newswire.ca
Waverley Pharma Announces Changes to Board of Directors
Newswire.ca
Waverley Pharma Business Update
The Globe and Mail
Waverley Pharma: Top 10 Undervalued Biotechnology Industry Stocks (WAVE)
Newswire.ca
Waverley Pharma Provides Business Update
The Globe and Mail
Waverley Pharma: Top 10 Undervalued Biotechnology Industry Stocks (WAVE)
The Globe and Mail
Waverley Pharma: Top 10 Undervalued Biotechnology Industry Stocks (WAVE)
Newswire.ca
Waverley Pharma Provides Update on its PARP-1 Inhibitor Program
The Globe and Mail
Waverley Pharma: Top 10 Undervalued Biotechnology Industry Stocks (WAVE)
The Globe and Mail
Waverley Pharma: Top 25 Undervalued TSX Venture Exchange Stocks (WAVE)

Profile

Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics focused on oncology. The company's product pipeline includes Bortezomib, Pemetrexed, Capecitabine, and Temozolomide, among others. The company operates in one business segment, the biopharmaceutical industry.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.